Owner MediGene AG

Convention US 17 April 2006 78862546

Filing Date 11 October 2006

Class 5 Pharmaceutical products for topical, intra-vaginal and/or intra-anal application, namely, pharmaceutical preparations for use in treating the skin diseases of warts, verruca vulgaris, verruca plantaris, verruca plana, flat condylomata, mosaic-type warts, butcher's warts, anogenital warts, condylomata accuminata, hyperplasia of the epidermis, recalcitrant cutaneous warts, herpes infection, genital and anal herpes infection, shingles, molluscum contagiosum, mycosis, mycosis fungoides, tinea, tinea pedis, pigmentation disorders, hyperpigmentation, hypopigmentation, vitiligo, melasma, atypical/displastic/melanocytic nevi, sun-damaged skin, removal of tattoos, psoriasis, neurodermitis, dermatitis, atopic dermatitis, cutaneous atopy, eczema, lichen planus, cutaneous lupus erythematosus, skin ulcers, rosacea, precancerous and cancerous lesions, increased proliferation of skin cells, actinic keratosis, actinic cheilitis, keloids, lentigo, hemangioma, epidermodysplasia verruciformis, bowen's disease, bowenoid papulosis, basal cell carcinoma, intraepithelial squamous cell carcinoma, melanoma, and other skin cancers, neoplasias, cervical dysplasia, cervical intraepithelial neoplasias, anal intraepithelial neoplasias, vulvar intraepithelial neoplasia, penile cancer, vulvovaginal cancer, anal carcinoma, cervical carcinoma, cutaneous t-cell lymphoma, alopecia, vulvodynia, keloid and hypertrophic scars, post surgical excision on scar cosmesis, hyperkeratosis, seborrhea, darier's disease, porokeratosis of mibelli, ichthyosis, xerosis, dartroud diathesis, acne, nasal papilloma, oral papilloma, focal epithelial hyperplasia, laryngeal papilloma, recurrent respiratory papillomatosis and conjunctival papilloma